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 Abstract:  Altered systemic iron metabolism is a key ele-
ment of uremia, and functional iron deficiency mainly 
related to subclinical inflammation makes it difficult to 
maintain proper control of anemia in chronic hemodialy-
sis patients (CHD). In the last decade, the hepatic hormone 
hepcidin has been progressively recognized as the master 
regulator of circulating iron levels through the modulation 
of cellular iron fluxes in response to iron stores, as well as 
to erythroid and inflammatory stimuli. Hepcidin is cleared 
by the kidney and progression of renal disease has been 
associated to increased serum hepcidin levels. This, in 
turn, reduces iron availability for erythropoiesis, suggest-
ing anti-hepcidin strategies for improving anemia control. 
Moreover, hepcidin has been recently implicated in the 
pathogenesis of long-term complications of dialysis, like 
accelerated atherosclerosis. Initial studies almost invari-
ably reported a sustained increase of serum hepcidin in 
chronic hemodialysis patients. Noteworthy, such studies 
included relatively few patients and controls that were 
poorly matched for major determinants of serum hepcidin 
at population level, i.e., age and gender. More recent data 
based on accurately matched larger series challenge the 
view that hepcidin is intrinsically increased in hemodi-
alysis patients, showing a marked inter- and intra-individ-
ual variability of hormone levels. Here we take a critical 
look to the data published so far on hepcidin levels in 
CHD, analyze the reasons underlying the discrepancies 
in available studies and the hepcidin variability in CHD, 
and point out the need for further studies in large series of 
well-characterized CHD patients and controls. 
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 Anemia and iron status in chronic 
hemodialysis patients 
 Anemia is observed in nearly all chronic hemodialysis 
(CHD) patients, and is associated with increased morbid-
ity and mortality. The pathogenesis is multifactorial [1], 
but a deficiency of erythropoietin (Epo) due to kidney 
injury is thought to play a major role, concomitant with 
reduced red blood cells life span, bleeding diathesis due 
to platelet dysfunction, and deficiency of iron, folate, 
and cobalamin. However, the persistence of anemia 
despite Epo, iron and vitamin supplementation sug-
gests a concomitant bone marrow hypo-responsiveness 
in these patients. Indeed, another major determinant of 
the anemia in CHD is the chronic inflammatory state, in 
which cytokines further decrease Epo production, induce 
apoptosis of erythroid precursors, and also reduce iron 
absorption and availability for erythropoiesis [2]. CHD 
is typically associated with alterations of circulating 
markers of iron metabolism, namely decreased transferrin 
saturation and increased serum ferritin levels, mostly due 
to iron retention in monocytes/macrophages [3]. The con-
sequence is  “ functional ” iron deficiency, which results in 
Epo resistance in 10% – 20% of cases, even in the presence 
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of apparently increased body iron stores, poorly available 
to the erythron. Routine monitoring of biochemical iron 
parameters and indices of adequate hemoglobinization of 
erythrocytes (e.g., transferrin saturation, mean corpuscu-
lar volume of erythrocytes) is therefore an essential com-
ponent of the management of CHD patients, attempting to 
provide adequate supplementation, when needed. 
 Hepcidin as a player in the anemia 
of CHD 
 In the last decade, it has been progressively clarified that 
hepcidin, a small peptide hormone mainly produced by 
the liver, represents the principal regulator of systemic iron 
metabolism (for a review, see [4]), via its ability to bind the 
cellular iron exporter ferroportin-1, blocking its iron trans-
port activity and increasing its degradation [5]. In entero-
cytes, hepcidin-induced ferroportin-1 internalization from 
the basolateral surface causes the retention of iron with 
subsequent loss by cell desquamation and inhibition 
of absorption, while the same process in macrophages 
blocks the release of iron recycled from erythrophagocy-
tosis [5]. Since the latter represents the primary source of 
iron in plasma [6], the final effect of hepcidin is reduc-
tion of plasma iron availability. Noteworthy, hepcidin is 
upregulated by both increased iron stores and inflamma-
tion, whereas it is reduced in response to iron deprivation, 
hypoxia and enhanced erythropoiesis [7]. In addition, 
hepcidin is cleared by the kidneys, and progression of 
chronic renal disease has been associated with a parallel 
rise in serum hepcidin levels [8 – 10]. This increase is partly 
counteracted by active clearance of this small hormone 
peptide during the dialytic procedure [11 – 13]. The clear-
ance of hepcidin is likely to be substantially influenced 
by the type of hemodialysis technique [12, 13], but this 
remains an area of further active research. Nevertheless, 
the majority of studies available until the beginning of 
this year have reported increased pre-dialytic serum 
hepcidin levels in CHD patients as compared to controls 
[10 – 12, 14 – 20]. It has therefore been hypothesized that 
in CHD patients increased hepcidin could aggravate 
functional iron deficiency by decreasing macrophage 
iron release and intestinal iron absorption, paving the 
way to the possible utilization of anti-hepcidin drugs 
for optimizing the management of anemia [9, 21]. In 
regards to this point, it is of interest to note that admi-
nistration of erythropoiesis stimulating agents (ESAs), by 
itself, has been reported to reduce hepcidin in patients 
with chronic kidney disease [15, 22]. This is likely due to 
hypoxia-inducible factor via Epo-induced erythropoiesis 
[23], and suggests that the beneficial effect of Epo in CHD 
may be partly mediated by normalization of iron delivery. 
 Is hyperhepcidinemia a constant 
and distinct feature of CHD? Novel 
data confuting the early reports 
 Available studies that reported circulating hepcidin levels 
in CHD patients as compared to healthy controls, includ-
ing some previous ones from our group, are presented in 
 Table 1 . They nearly all invariably reported increased hep-
cidin levels in CHD. In most of these studies, hepcidin was 
measured by mass spectrometry-based assays, which are 
currently considered among the most accurate ones for 
measuring hepcidin-25, the iron bioactive isoform of the 
hormone [25, 26]. Other well-performing immunoassays 
[26, 27], while generally showing a high correlation with 
validated mass spectrometry-based assays, are charac-
terized by variable degree of cross-reactivity with minor 
circulating hepcidin isoforms like hepcidin-20 [28]. The 
biological meaning of these isoforms, lacking amino acids 
at the N-terminus essential for proper functional interac-
tion with ferroportin [29], is still uncertain. Nevertheless, 
they also have been reported unusually elevated in renal 
patients [12, 26]. Of note, nearly all the early studies on 
CHD were characterized by the evaluation of a limited 
number of patients ( < 100), and even smaller number of 
controls, which in the majority of cases were not ade-
quately matched for demographic features ( Table 1 ). 
Similarly, these controls were not screened for the pres-
ence of other potential confounders, such as the presence 
of subclinical iron deficiency and/or common genetic 
variants influencing iron metabolism, i.e., mutation in the 
HFE gene ( Table 1 ). Our most recent results [24], using a 
widely validated mass spectrometry-based assay [30] in 
one of the largest CHD cohort (n = 155) reported so far, did 
not detect a clear and generalized increase of hepcidin-25 
levels as compared to healthy controls (n = 188) from the 
Val Borbera Study [31], who were meticulously matched 
for age, gender, and genetic background. The discrepancy 
as compared to apparently uniform data from previous 
reports may be explained by at least two orders of reasons. 
The first deals with the above-mentioned relatively low 
number of subjects included, and, in particular, with the 
poor matching between CHD patients and controls as 
regards to age and gender. Indeed, while renal patients 
are usually elderly, controls were generally enrolled 
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among young people ( Table 1 ). In most of the studies, 
the mean age of controls was around 35 years, while that 
of CHD patients was   ≥  60 years. Two recently completed 
large population surveys, the Val Borbera Study [31] and 
the Nijmegen Biomedical Study [32], including 1657 and 
2998 subjects, respectively, have concordantly demon-
strated that age and gender are major determinants of 
serum hepcidin levels. This is particularly important for 
females, as it has been pointed out that post-menopausal 
women have hepcidin levels about three-fold higher than 
pre-menopausal women [31, 32]. Due to this new aware-
ness, in our most recent study [24] we devoted particular 
accuracy in selecting an appropriate number of controls 
(the largest reported so far) from the Val Borbera dataset, 
to allow proper matching with CHD patients for age and 
gender. 
 The second reason for discrepancy with earlier 
reports is related to the iron status of both CHD patients 
and controls. All previous studies concordantly suggested 
that the regulation of hepcidin by iron stores is preserved 
in CHD patients, as illustrated by the fact that serum fer-
ritin levels were invariably among the strongest predic-
tors of hepcidin levels in CHD (Table 1), as observed in the 
general population [31, 32]. Of note, the CHD population 
investigated in our last study [24] was enrolled in a center 
characterized by a clinical policy favoring relatively low 
iron supplementation to avoid iron toxicity. Indeed, the 
median ferritin level in this CHD population was  “ only ” 
265  μ g/L (interquartile range 155 – 411  μ g/L), while, e.g., in 
the previous study by Ashby and colleagues [15] the mean 
ferritin level in 94 CHD patients was 550  μ g/L (95% CI 291 
and 1014  μ g/L, respectively). Moreover, again in the effort 
to select the most appropriate controls, we included only 
control subjects with biochemically documented normal 
iron status. To this purpose, we considered as exclusion 
criteria ferritin levels lower than 30  μ g/L and 40  μ g/L 
in females and males, respectively, TS lower than 16%, 
and decreased levels of hemoglobin. This enabled us to 
 Table 1   Available studies comparing serum hepcidin levels between adult CHD patients and healthy controls. 
 Reference    CHD patients: n 
of subjects, age 
(years) 
   Healthy controls: 
n of subjects, 
age (years) 
   Age and sex 
matching 
 (CHD vs. 
controls) 
   Method for 
hepcidin 
quantification 
   Hepcidin 
results a 
   Hepcidin 
determinants 
 Tomosugi [10]    40    16    n.a.    MS-based 
(semiquantitative) 
   Higher in CHD    FT, IL-6 
    Age n.a.    Age n.a.            
 Zaritsky [11]    33    24    Sex matched;    Competitive ELISA    Higher in CHD 
(total hepcidin) 
   FT, TS, CRP 
    60.3 ± 20.7    28.4 ± 6.6    Age unmatched         
 Campostrini [12]    54    57    Sex matched;    MS-based 
(quantitative) 
   Higher in CHD    FT 
    67 ± 14    35 ± 15    Age unmatched         
 Valenti [14]    65    57    Sex matched;    MS-based 
(quantitative) 
   Higher in CHD    FT, CRP, HFE 
mutations     65.5 ± 12    35 ± 15    Age unmatched       
 Ashby [15]    94    64    Sex and age 
unmatched 
   Radioimmunoassay 
(RIA) 
   Higher in CHD 
(total hepcidin) 
   Hb, Epo dose 
    64.6 (39.2 – 83.0) b    Age n.a.          
 Peters [16]    48    24    Sex and age 
unmatched 
   MS-based 
(quantitative) 
   Higher in CHD    FT, serum iron 
    61 ± 15    39 ± 12           
 Tessitore [17]    56    57    Sex matched;    MS-based 
(quantitative) 
 
   Higher in CHD    FT, sTfR, 
hypochromic 
red cells 
    67 ± 14    35 ± 15    Age unmatched       
 Ghoti [18]    21    63    Sex and age 
matched 
   MS-based 
(quantitative) 
   Higher in CHD    n.a. 
    63.4 ± 12.9    63.4 ± 12.9           
 Costa [19]    33    17    n.a. c    MS-based 
(quantitative) 
   Higher in CHD    CRP 
    59.5 ± 17.6    Age n.a.            
 Kurugano [20]    198    33    Sex and age 
unmatched 
   MS-based 
(quantitative) 
   Higher in CHD    FT, transferrin, 
IL-6 d     58 ± 11    34 ± 8         
 Pelusi [24]    155    188    Sex and age 
matched 
 
   MS-based 
(quantitative) 
 
   Similar in CHD 
and controls 
 
   FT, CRP, genetic 
factors (HFE 
and TMPRSS6) 
    64.3 ± 14    60 ± 17        
 a refers to  “ hepcidin-25 isoform ” where not otherwise specified;  b 95% confidence interval;  c matched as far as possible for sex and age;  d 
IL-6 determinant of hepcidin only in subjects with CRP  > 0.3 mg/dL. CBC, complete blood count; CHD, chronic hemodialysis; CKD, chronic 
kidney disease; CRP, C-reactive protein; FT, ferritin; sTfR, soluble transferrin receptor; IL-6, interleukin-6; MS, mass spectrometry; TS, 
transferrin saturation %. 
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avoid the common pitfall of enrolling controls subjects 
with subclinical low iron status, and ensuing lower than 
normal hepcidin levels. 
 Finally, blood samples from all CHD patients were 
taken after an inter-dialytic period of 3  days [33], thus 
excluding any possible clearance effect of recent dialysis 
procedures. For all the reasons outlined above, we are 
confident that the lack of difference in mean hepcidin 
levels between CHD patients and controls [24] was likely 
the result of a balance between flawless controls matched 
for age/gender and without even a subclinical iron defi-
ciency, and, also of CHD patients characterized on average 
by lower iron stores than those usually observed in most 
of the previously published cohorts. Further support 
to this balanced view arises from our direct experience. 
During the same period in which we performed the last 
large study on CHD [24], we also analyzed in our labora-
tory CHD samples from another dialysis center using a 
different policy as regards to intravenous iron supplemen-
tation. In this particular setting, including selected CHD 
patients with MR-ascertained iron overload and serum fer-
ritin levels  > 1000  μ g/L [18], we observed serum hepcidin 
levels substantially higher than controls even after careful 
matching using the same criteria outlined above for the 
patients enrolled in Milan [24]. In agreement with the 
view that iron status rather than uremia per se appears as 
the major determinant of hepcidin in CHD, serum ferritin 
was the major predictor of hormone level in nearly all the 
studies published so far, which also included CRP as covar-
iate (Table 1). Similarly, when we excluded from the analy-
sis of CHD patients enrolled in Milan those with possible 
 “ functional ” iron deficiency (i.e., with ferritin levels  < 200 
 μ g/L or TS  < 30%), we showed that hepcidin levels were 
significantly higher in CHD patients than in controls (Sup-
plemental Data, Figure 1, which accompanies the article at 
 http://www.degruyter.com/view/j/cclm.2014.52.issue-4/
issue-files/cclm.2014.52.issue-4.xml ). Overall, our results 
suggest that the current  “ dogma ” of hyperhepcidinemia 
as a constant feature of CHD patients need to be reconsid-
ered by further studies based on careful control selection 
and matching. 
 Clinical correlates of hepcidin levels 
in CHD patients 
 An unpublished sub-analysis of our entire CHD cohort 
with complete clinical and genetic characterization 
further supports the concept of the high variability of hep-
cidin levels in CHD patients, as well as the lack of hepcidin 
upregulation in some of them. Supplemental data, Table 
1 shows the main features of these patients stratified 
according to hepcidin-25 quartiles. As expected, the major 
determinant of hepcidin levels was represented by serum 
ferritin, with a lower contribution by inflammation. Most 
patients in the lowest hepcidin quartile ( < 0.55 nM) were 
likely iron deficient, as estimated by ferritin and TS levels. 
They also had significantly higher body mass index, 
although it was not possible to discriminate whether this 
could be explained by inadequate control of body fluids or 
by increased adiposity. 
 An adequate iron balance was likely present in 
most patients included in the second and third hepci-
din quartiles (0.56 – 17.83 nM), showing ferritin levels 
mostly within recommended ranges for these patients 
and absence of inflammation. However, patients in the 
top quartile of hepcidin ( > 17.83 nM) had either subclini-
cal inflammation (as detected by increased CRP levels) 
and/or increased iron stores, resulting in decreased iron 
availability and increased need for Epo. Interestingly, the 
wide variability of hepcidin levels among patients did 
not appear to be entirely explained by differences in iron 
stores and inflammation, as hepcidin/ferritin and hep-
cidin/CRP ratios increased with hepcidin quartiles. It is 
therefore likely that additional factors related to secre-
tion, processing, and clearance affect hepcidin levels 
in CHD. The hepcidin/ferritin ratio observed in lowest 
hepcidin quartiles is lower than in controls [24], para-
doxically indicating inappropriately low hepcidin levels 
for the level of iron stores and inflammation. This would 
suggest that hepcidin clearance by the hemodialysis pro-
cedure plays a role in maintaining low/normal serum 
hepcidin levels in CHD patients without increased iron 
stores [34]. In a previous pilot study, no significant differ-
ences in hepcidin clearance could be detected according 
to the dialysis technique [12], while hemodiafiltration, 
which would facilitate the clearance of small peptides 
such as hepcidin, has been recently reported superior 
to conventional hemodialysis [35]. However, the linear 
correlation between serum hepcidin and calcium levels 
(Supplemental data, Table 1) does not clearly support a 
predisposing effect of the failure to correct severe uremia 
on the development of high hepcidin levels [34]. It is cur-
rently unknown whether calcium levels or parathyroid 
hormone and vitamin D dependent signaling pathways 
may affect hepcidin release. Finally, we confirm the role 
of genetic factors regulating iron metabolism, namely the 
C282Y HFE mutation of hereditary hemochromatosis [14] 
and the TMPRSS6 A736V polymorphism [24] in modu-
lating hepcidin production in CHD (Supplemental data, 
Table 1). 
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 Potential clinical usefulness of 
hepcidin determination in CHD 
patients 
 Recent data based on MRI suggest that a substantial 
fraction of CHD patients receiving Epo and intrave-
nous iron supplementation have hepatic iron overload 
[19, 36]. This illustrates the need for updating guidelines 
on the amount of iron infused in these patients which 
may promote not only organ damage, but also a vicious 
cycle because of increased hepcidin production and 
ensuing iron maldistribution, without improving anemia. 
Whether or not evaluation of hepcidin levels may help 
clinicians in driving iron supplementation therapy in CHD 
patients is matter of debate. To date, the relatively larger 
study (n = 56) did not show hepcidin as a useful predic-
tor of hemoglobin response to i.v. iron [17]. However, this 
study had some limitations like possible underpowering 
and lack of a control group, so that larger trials comparing 
hepcidin-driven to standard therapeutic approaches are 
eagerly awaited. 
 Another intriguing application of hepcidin in CHD has 
recently emerged, as regards to cardiovascular complica-
tions, which represent a major cause of morbidity and 
mortality in these patients. Experimental data suggest that 
hepcidin may be implicated in the pathogenesis of athero-
sclerosis though its ability to induce iron accumulation 
and oxidative stress within macrophages of the arterial 
walls [37]. Indeed, hepcidin levels have been associated 
 Figure 1   Schematic representation of the determinants of hepcidin 
levels in chronic hemodialysis patients. 
 Genetic background: presence of C282Y and H63D HFE and/or of the 
A736V TMPRSS6 polymorphisms; GFR: glomerular filtration rate; TS: 
transferrin saturation. 
with both reduced cholesterol efflux in macrophages [37], 
and release of the atherogenic chemokine macrophage 
chemoattractant protein-1 (MCP-1) [38]. In CHD patients, 
hepcidin levels have been recently shown to correlate 
with arterial stiffness [39], as well as to predict cardiovas-
cular events independently of inflammation [40]. Thus, 
hepcidin appears to be a good candidate in explaining 
accelerated atherosclerosis in CHD patients, and its meas-
urement may help to stratify individual patients risk. 
However, besides known difficulties in technical stand-
ardization [25, 26], another factor specific to CHD that may 
limit the use of hepcidin assay in this setting is the large 
inter- and intra-individual variability [33]. In this respect, 
future studies should be carefully standardized for any 
possible confounder such as, dialysis technique, distance 
to the last dialytic session and to last administration of 
iron/Epo, and subclinical infective episodes. 
 Conclusions 
 The relatively large number of studies published so far has 
generated the common idea that hepcidin is invariably 
high in CHD, with clinical implications lower than expected 
[33]. However, it is now clear that the quality of most of 
these studies was suboptimal in terms of numbers, control 
of confounders, and clinical heterogeneity (Table 1). 
More rigorous recent data are not consistent with hyper-
hepcidinemia as an intrinsic and constant feature of CHD 
patients. In this setting, undoubtedly, several factors drive 
an increase of serum hepcidin, including severe reduction 
in glomerular filtration rate, frequent iron supplemen-
tation, and inflammation. However, hepcidin is fairly 
well cleared during dialysis, and the regulation by iron 
appears to be relatively preserved in CHD patients, even 
during depletion. As a consequence, although hepcidin 
is frequently increased in CHD, the net result in the indi-
vidual patient is highly variable depending on iron stores, 
inflammatory status, genetic factors, the dialysis tech-
nique, and other factors still unknown.  Figure 1 recapitu-
lates the many opposing stimuli determining hepcidin 
levels in CHD patients. The variability of hepcidin levels 
in CHD patients may have important clinical and thera-
peutic implications, even beyond the classical target of 
anemia correction. For example, increased serum hepci-
din levels may herald a pathological iron overload induc-
ing interruption of intravenous iron supplementation, as 
well as an increased risk of cardiovascular complications. 
CHD patients with sustained hyperhepcidinemia may be 
good candidates for the use of hepcidin antagonists [4] to 
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promote proper iron utilization for erythropoiesis. Avail-
able studies on hepcidin level as a guide to intravenous 
iron supplementation in CHD are limited to the observa-
tion of a lack of correlation with hemoglobin increase in 
relatively small and unselected populations [17]. However, 
the subgroup of CHD patients with repeatedly normal to 
low serum hepcidin levels may represent the ideal target 
for safe and effective iron supplementation. 
 In summary, we are still at the beginning of the hepci-
din era in CHD, and there is urgent need of further studies 
in large series of well-characterized CHD patients and 
controls. 
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